ClinicalTrials.gg

Program

Betamethasone

Also written as “Ropivacaine + Clonidine + Betamethasone”, “Fixed Dose Etoricoxib + Betamethasone” and “calcipotriol and betamethasone (LEO 80185 gel)”.

Its studies are mostly in Psoriasis · Bursitis · Hip Fractures · Rhinitis, led by 6 companies.

Furthest: phase 4, since Jan 17, 20068 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
LEO Pharma30 open or runningphase 3since Jan 17, 2006Jan 17, 2006none ahead
Abbott10 open or runningphase 3since Dec 12, 2007Dec 12, 2007none ahead
Cartiva10 open or runningphase 2since Feb 17, 2014Feb 17, 2014none ahead
Laboratorios Silanes S.A. de C.V.10 open or runningphase 3since Dec 28, 2025Dec 28, 2025none ahead
Merck10 open or runningphase 4since Aug 20, 2009Aug 20, 2009none ahead
Tolmar10 open or runningphase 1since Apr 6, 2017Apr 6, 2017none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 17, 2006First study: phase 3 study in PsoriasisNew to LEO PharmaLEO Pharma · NCT00279162 · 160 enrolled · United States
  2. Dec 12, 2007Abbott's first study: phase 3 study in PsoriasisNew to AbbottAbbott · NCT00574249 · 730 enrolled · Austria, Belgium, Czech Republic and more
  3. Apr 29, 2008Phase 3 study in Psoriasis VulgarisLEO Pharma · NCT00670241 · 458 enrolled · Canada
  4. Aug 20, 2009Merck's first study: phase 4 study in RhinitisNew to MerckMerck · NCT00963573 · 100 enrolled
  5. Aug 25, 2010Phase 3 study in Psoriasis VulgarisLEO Pharma · NCT01188928 · 1,152 enrolled · United States
  6. Feb 17, 2014Cartiva's first study: phase 2 study in Hip FracturesNew to CartivaCartiva · NCT02066844 · 40 enrolled · United States
  7. Apr 6, 2017Tolmar's first study: phase 1 study in Scalp PsoriasisNew to TolmarTolmar · NCT03122353 · 699 enrolled · United States
  8. Dec 28, 2025Laboratorios Silanes S.A. de C.V.'s first study: phase 3 study in BursitisNew to Laboratorios Silanes S.A. de C.V.Laboratorios Silanes S.A. de C.V. · NCT07328022 · 89 enrolled · Mexico

TargetBeta

NR3C1 →read by rule
“Glucocorticoid receptor agonist”ChEMBL 37, by rule

Other programs on NR3C1

ProgramCompanyFurthest phaseStudies
DexamethasoneruleAbbViephase 4174
BudesonideruleAstraZenecaphase 4167
fluticasone furoateruleGlaxoSmithKlinephase 497
PrednisoneruleJohnson & Johnsonphase 465
BeclomethasoneruleChiesi Farmaceuticiphase 446
PrednisoloneruleSanofiphase 434
betamethasone dipropionateruleLEO Pharmaphase 427
MethylprednisolonerulePfizerphase 423
dexamethasone phosphateruleeyegate-pharmaceuticals-incphase 421
vamorolonerulereveragen-biopharma-incphase 411
Triamcinoloneruleresearch-insight-llcphase 45
relacorilantruleCorcept Therapeuticsphase 322

Studies

All 8 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07328022Bursitis · Mexico3CompletedLaboratorios Silanes S.A. de C.V.Aug 20, 202589
NCT03122353Scalp Psoriasis · United States1CompletedTolmarNov 15, 2017699
NCT02066844Hip Fractures · United States2CompletedCartivaAug 201440
NCT01188928Psoriasis Vulgaris · United States3CompletedLEO PharmaMar 20111,152
NCT00963573Rhinitis4CompletedMerckNov 2006100
NCT00670241Psoriasis Vulgaris · Canada3CompletedLEO PharmaFeb 2009458
NCT00574249Psoriasis · Austria, Belgium, Czech Republic and more3CompletedAbbottOct 2008730
NCT00279162Psoriasis · United States3CompletedLEO Pharma160

How it is read

Names in the registry

  • “Ropivacaine + Clonidine + Betamethasone”, 3 entries
  • “Fixed Dose Etoricoxib + Betamethasone”, 1 entry
  • “calcipotriol and betamethasone (LEO 80185 gel)”, 1 entry
  • “Calcipotriol plus betamethasone”, 1 entry
  • “Calcipotriene/betamethasone gel and ointment”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.